Impact of high androgen levels on IVF success in women with PCOS
Effect of Hyperandrogenism on IVF Success Rates in PCOS Patients
This study is testing how high androgen levels affect the success of IVF in women with polycystic ovary syndrome (PCOS) to help improve their chances of having a baby.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 188 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | Female |
| Sponsor | Clinique Ovo Industry-sponsored |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT05555680 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how hyperandrogenism affects the outcomes of in vitro fertilization (IVF) in women diagnosed with polycystic ovary syndrome (PCOS). It aims to assess the relationship between elevated androgen levels and the quality of oocytes and embryos, as well as overall IVF success rates. The study will include women aged 18 to 39 who have a sufficient number of oocytes collected or a high anti-mullerian hormone level. By analyzing these factors, the research seeks to provide insights into improving IVF outcomes for PCOS patients.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 to 39 with PCOS who have a history of retrieving at least 15 oocytes or have a high anti-mullerian hormone level.
Not a fit: Patients with male factor infertility requiring surgical sperm retrieval or those with recurrent pregnancy losses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved IVF success rates for women with PCOS by identifying the impact of hyperandrogenism on reproductive outcomes.
How similar studies have performed: Previous studies have indicated that hyperandrogenism negatively impacts IVF outcomes in PCOS patients, suggesting that this research builds on established findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women between ages of 18 - 39 inclusively * ≥15 oocytes collected on the day of oocyte retrieval and/or anti-mullerian hormone (AMH) ≥ 4.0 ng/ml in the participant's medical chart in the last 24 months Exclusion Criteria: * Male factor necessitating testicular sperm aspiration (TESA), testicular sperm extraction (TESE) or micro-TESE * Fertility preservation * Recurrent pregnancy losses (RPL) (defined as 2 or more failed clinical pregnancies as documented by ultrasonography or histopathologic examination,or 3 or more failed pregnancies before 14 weeks of gestation) * Oocyte donation * Medical diagnosis of non classic congenital adrenal hyperplasia diagnosed based on 17 hydroxyprogesterone level
Where this trial is running
Montreal, Quebec
- Clinique Ovo — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Joanne Benoit, MD — Clinique Ovo
- Study coordinator: Nelly Delouya, RN
- Email: n.delouya@cliniqueovo.com
- Phone: 15147982000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.